Effects of Treatment With N- Acetylcysteine on Visual Outcomes in Patients With Retinitis Pigmentosa
Launched by SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES · Apr 27, 2021
Trial Information
Current as of May 14, 2025
Unknown status
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • RP patients with the best-corrected visual acuity (BCVA) between 20/30 and 20/120.
- Exclusion Criteria:
- • Patients with other types of retinal dystrophy
- • Systemic or syndromic RP
- • RP patients with cystoid macular edema (CME) and the presence of cystoid changes in the foveal area
- • RP patients with other concomitant ocular diseases
- • RP patients with a history of any ocular surgery or intravitreal injection within 6 months before the study enrollment
- • RP patients who have received any supplemental drugs during the past three months before the study enrollment
About Shahid Beheshti University Of Medical Sciences
Shahid Beheshti University of Medical Sciences, located in Tehran, Iran, is a leading institution dedicated to advancing healthcare through innovative research and education. Renowned for its commitment to medical excellence, the university actively sponsors clinical trials aimed at improving patient outcomes and enhancing medical practices. With a multidisciplinary approach, it collaborates with healthcare professionals and researchers to explore new treatments and interventions, contributing significantly to the global body of medical knowledge. The institution is dedicated to upholding the highest ethical standards in research, ensuring the safety and well-being of participants while fostering a culture of scientific inquiry and discovery.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Tehran, , Iran, Islamic Republic Of
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials